[1] BJORNSSON E S, BERGMANN O M, BJORNSSON H K,et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology, 2013, 144(7): 1419-1425. [2] DU J X, SHEN L. Drug-induced hepatic lesions:Clinical analysis of 170 cases. J China Pharm(中国药房), 2008, 19(2): 138-139. [3] OSTAPOWICZ G, FONTANA R J, SCHIODT F V,et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med, 2002, 137(12): 947-954. [4] WATKINS P B. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther, 2011, 89(6): 788-790. [5] AITHAL G P, WATKINS P B, ANDRADE R J, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 2011, 89(6): 806-815. [6] CAI W M. Pharmacogenomics and individualized medicine . Chin Pharm J(中国药学杂志),2007,42(24):1841-1844. [7] YUAN L, KAPLOWITZ N. Mechanisms of drug-induced liver injury. Clin Liver Dis, 2013, 17(4): 507-518. [8] CORSINI A, BORTOLINI M. Drug-induced liver injury: The role of drug metabolism and transport. J Clin Pharmacol, 2013, 53(5): 463-474. [9] ANTOINE D J, WILLIAMS D P, PARK B K. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: State of the science. Expert Opin Drug Metab Toxicol, 2008, 4(11): 1415-1427. [10] PICHLER W J, NAISBITT D J, PARK B K. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol, 2011, 127(3 suppl): 74-81. [11] REESE M, SAKATIS M, AMBROSO J, et al. An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. Chem Biol Interact, 2011, 192(1-2): 60-64. [12] DALY A K, DAY C P. Genetic association studies in drug-induced liver injury. Drug Metab Rev, 2012, 44(1): 116. [13] HIRSCHHORN J N, DALY M J. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet, 2005, 6(2): 95-108. [14] CHUNG W H, HUNG S I, HONG H S, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature, 2004, 428(6982): 486. [15] MALLAL S, NOLAN D, WITT C,et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002, 359(9308): 727-732. [16] HUGHES A R, SPREEN W R, MOSTELLER M, et al. Pharmacogenetics of hypersensitivity to abacavir: From PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J, 2008, 8(6): 365-374. [17] STRICKER B H, BLOK A P, CLAAS F H,et al. Hepatic injury associated with the use of nitrofurans: A clinicopathological study of 52 reported cases. Hepatology, 1988, 8(3): 599-606. [18] BERSON A, FRENEAUX E, LARREY D,et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol, 1994, 20(3): 336-342. [19] HAUTEKEETE M L, HORSMANS Y, VAN WAEYENBERGE C,et al. HLA Association of amoxicillin-clavulanate--induced hepatitis. Gastroenterology, 1999, 117(5): 1181-1186. [20] O'DONOHUE J, OIEN K A, DONALDSON P,et al. Co-amoxiclav jaundice: Clinical and histological features and HLA class II association. Gut, 2000, 47(5): 717-720. [21] DONALDSON P T, DALY A K, HENDERSON J, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol, 2010, 53(6): 1049-1053. [22] ANDRADE R J, CAMARGO R, LUCENA M I,et al. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf, 2004, 3(4): 329-344. [23] LUCENA M I, MOLOKHIA M, SHEN Y,et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology, 2011, 141(1): 338-347. [24] RUSSMANN S, KAYE J A, JICK S S,et al. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol, 2005, 60(1): 76-82. [25] DALY A K, DONALDSON P T, BHATNAGAR P,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet, 2009, 41(7): 816-819. [26] CHESSMAN D, KOSTENKO L, LETHBORG T,et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 2008, 28(6): 822-832. [27] ALFIREVIC A, PIRMOHAMED M. Predictive genetic testing for drug-induced liver injury: Considerations of clinical utility. Clin Pharmacol Ther, 2012, 92(3): 376-380. [28] SPRAGGS C F, BUDDE L R, BRILEY L P,et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol, 2011, 29(6): 667-673. [29] GONZALEZ-GALARZA F F, CHRISTMAS S, MIDDLETON D,et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res, 2011, 39:913-919. [30] GAO S C, GUI X E, DENG L P,et al. Nevirapine related hepatotoxicity: The prevalence and risk factors in a cohort of ART na(i)ve Han Chinese with AIDS. Chin J Hepatol(中华肝脏病杂志), 2010, 18(9): 689-693. [31] HAAS D W, MOOTSIKAPUN P, RUXRUNGTHAM K,et al. Clinical perspectives on human genetic screening to prevent nevirapine toxicity. Per Med, 2012, 9(7): 773-782. [32] MARTIN A M, NOLAN D, JAMES I,et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. Aids, 2005, 19(1): 97-99. [33] YUAN J, GUO S, HALL D,et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. Aids, 2011, 25(10): 1271-1280. [34] PHILLIPS E, BARTLETT J A, SANNE I, et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr, 2013, 62(2): 55-57. [35] MIZUSHIMA M, IWATA N, FUJIMOTO T T, et al. Patient characteristics in ticlopidine hydrochloride-induced liver injury: Case-control study. Hepatol Res, 2005, 33(3): 234-240. [36] HIRATA K, TAKAGI H, YAMAMOTO M, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: A preliminary case-control study. Pharmacogenomics J, 2008, 8(1): 29-33. [37] SAITO S, OTA S, YAMADA E ,et al. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens, 2000, 56(6): 522-529. [38] XIA L F, FU D X. A dverse reaction of ticlopidine. Chin J Clin Rational Drug Use(临床合理用药杂志), 2011, 04(24): 39-42. [39] LEE W M, LARREY D, OLSSON R,et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf, 2005, 28(4): 351-370. [40] HARENBERG J, JORG I, WEISS C. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int J Toxicol, 2006, 25(3): 165-169. [41] KINDMARK A, JAWAID A, HARBRON C G,et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J, 2008, 8(3): 186-195. [42] GIBERT M, SANCHEZ-MAZAS A. Geographic patterns of functional categories of HLA-DRB1 alleles: A new approach to analyse associations between HLA-DRB1 and disease. Eur J Immunogenet, 2003, 30(5): 361-374. [43] SINGER J B, LEWITZKY S, LEROY E,et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet, 2010, 42(8): 711 714. [44] URBAN T J, GOLDSTEIN D B, WATKINS P B. Genetic basis of susceptibility to drug-induced liver injury: What have we learned and where do we go from here. Pharmacogenomics, 2012, 13(7): 735-738. [45] ZHOU Y, YANG L, LIAO Z, et al. Epidemiology of drug-induced liver injury in China:A systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol, 2013, 25(7): 825-829.